4983-28-2

Basic information

• Product Name: 2-Chloro-5-hydroxypyrimidine
• Synonyms: 2-Chloro-5-hydroxypyrimidine;2-Chloropyrimidin-5-ol;5-Pyrimidinol, 2-chloro- (7CI,8CI,9CI);2-Chloro-5-hydroxypyrimid...;2-Chloropyrimidin-5-ol, 2-Chloro-5-hydroxy-1,3-diazine;5-PyriMidinol,2-chloro-
• CAS NO: 4983-28-2
• Molecular Formula: C₄H₃ClN₂O
• Molecular Weight: 130.53
• EINECS: -0
• Product Categories: PYRIMIDINE;pharmacetical;Pyrimidines;Heterocycle-Pyrimidine series
• Mol File: 4983-28-2.mol
• Article Data: 12

Chemical Properties

• Melting Point: 195-196 °C
• Boiling Point: 328.1 °C at 760 mmHg
• Flash Point: 152.3 °C
• Appearance: /
• Density: 1.513 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6.17±0.23(Predicted)
• CAS DataBase Reference: 2-Chloro-5-hydroxypyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-hydroxypyrimidine(4983-28-2)
• EPA Substance Registry System: 2-Chloro-5-hydroxypyrimidine(4983-28-2)

Safety Data

• Hazardous Substances Data: 4983-28-2(Hazardous Substances Data)

Usage

Uses

2-Chloro-5-hydroxypyrimidine is an intermediate used to synthesize tandospirone derivatives with anxiolytic activities.

Upstream product

• 56621-90-0 2-chloro-5-aminopyrimidine 
• 1003845-06-4 (2-chloropyrimidin-5-yl)boronic acid 
• 22536-65-8 2-chloro-5-methoxy-pyrimidine 
• 56622-03-8 2-Chloro-5-(dimethylaminomethyleneamino)pyrimidine 

Downstream Products

• 138274-14-3 5-(benzyloxy)-2-chloropyrimidine 
• 1350730-12-9 2-chloro-5-(3-(pyrrolidin-1-yl)phenoxy)pyrimidine 
• 1453211-57-8 2-chloro-5-[(3,5-dimethoxyphenyl)methoxy]pyrimidine 
• 1453211-61-4 2-chloro-5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidine 
• 1453211-59-0 2-chloro-5-[1-(3,5-dimethoxyphenyl)ethoxy]pyrimidine 
• 1453207-63-0 5-[(2,6-difluorobenzyl)oxy]-N-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine 
• 1453211-58-9 2-chloro-5-[(2,6-dichloro-3,5-dimethoxybenzyl)oxy]pyrimidine 
• 1453211-80-7 2-chloro-5-(1-(2,6-dichloro-3,5-dimethoxyphenyl)ethoxy)pyrimidine 

Relevant articles and documents

Preparation method of 2-chloro-5-hydroxypyrimidine

The invention relates to a preparation method of 2-chloro-5-hydroxypyrimidine. The preparation method is characterized by comprising the following steps: step a, adding 2-chloro-5-methoxypyrimidine and an organic acid solvent in a reaction vessel, stirring uniformly, adding hydrobromic acid and methionine, and stirring and heating for carrying out reflux reaction for 3-8 hours; step b, cooling toroom temperature after the reaction, adding water, carrying out solvent extraction several times, and merging organic phases; step c, washing and drying the organic phases, and then concentrating andpurifying to obtain a pale yellow solid target product. The preparation method has the beneficial effects that the ratio of raw materials is optimized, so that the impurity content of the product is significantly reduced; a hydrobromic acid-methionine system replaces boron tribromide for performing demethylation reaction, so that the cost of the raw materials is effectively reduced, and the product purity and the reaction yield are greatly improved.

Orally Bioavailable Metal Chelators and Radical Scavengers: Multifunctional Antioxidants for the Coadjutant Treatment of Neurodegenerative Diseases

Neurodegenerative diseases are associated with oxidative stress that is induced by the presence of reactive oxygen species and the abnormal cellular accumulation of transition metals. Here, a new series of orally bioavailable multifunctional antioxidants (MFAO-2s) possessing a 2-diacetylamino-5-hydroxypyrimidine moiety is described. These MFAO-2s demonstrate both free radical and metal attenuating properties that are similar to the original published MFAO-1s that are based on 1-N,N′-dimethylsulfamoyl-1-4-(2-pyrimidyl)piperazine. Oral bioavailability studies in C57BL/6 mice demonstrate that the MFAO-2s accumulate in the brain at significantly higher levels than the MFAO-1s while achieving similar neural retina levels. The MFAO-2s protect human neuroblastoma and retinal pigmented epithelial cells against hydroxyl radicals in a dose-dependent manner by maintaining cell viability and intracellular glutathione levels. The MFAO-2s outperform clioquinol, a metal attenuator that has been investigated for the treatment of Alzheimer's disease.

TYROSINE KINASE INHIBITORS

The present invention relates to pyridazin-4(1H)-one derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.